Abstract
A study was made to evaluate bone turn-over in rheumatoid arthritis (RA) patients treated with infliximab. Twenty-two patients with established RA were included. In all patients, biochemical markers of osteoporosis: osteocalcin (BGP), alkaline phosphatase (bone isoenzyme), deoxypyridinoline (Dpd), acute phase proteins (CRP, AGP, ACT, AGP-RC), and interleukin 6 (IL-6) were determined before treatment, at week 30, and at week 46. Two markers (BGP, Dpd) were significantly decreased at both weeks 30 and 46. Moreover, a fall in serum levels of acute phase proteins and IL-6 was seen. The results suggest that anti-TNF treatment with infliximab not only decreases activity of inflammation but also may slow down bone turn-over. Further research is needed to assess its potential in reducing risk of osteoporosis in RA.
MeSH terms
-
Acute-Phase Proteins / metabolism
-
Adult
-
Aged
-
Alkaline Phosphatase / blood
-
Amino Acids / blood
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal / pharmacology
-
Antirheumatic Agents / administration & dosage*
-
Antirheumatic Agents / pharmacology
-
Arthritis, Rheumatoid / blood*
-
Arthritis, Rheumatoid / complications
-
Arthritis, Rheumatoid / drug therapy*
-
Biomarkers / blood
-
Bone Density / drug effects
-
Bone Resorption / drug therapy
-
Bone Resorption / prevention & control
-
Case-Control Studies
-
Dose-Response Relationship, Drug
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
Humans
-
Infliximab
-
Interleukin-6 / blood
-
Male
-
Middle Aged
-
Osteocalcin / blood
-
Osteoporosis / blood*
-
Osteoporosis / etiology
-
Osteoporosis / prevention & control
-
Receptors, Tumor Necrosis Factor / administration & dosage*
-
Severity of Illness Index
-
Time Factors
-
Treatment Outcome
Substances
-
Acute-Phase Proteins
-
Amino Acids
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
Biomarkers
-
Interleukin-6
-
Receptors, Tumor Necrosis Factor
-
Osteocalcin
-
deoxypyridinoline
-
Infliximab
-
Alkaline Phosphatase